Skip to main content
Pharos iBio Co., Ltd. logo

Pharos iBio Co., Ltd. — Investor Relations & Filings

Ticker · 388870 ISIN · KR7388870008 KO Professional, scientific and technical activities
Open in API
Filings indexed 83 across all filing types
Latest filing 2023-04-10 Audit Report / Informat…
Country KR South Korea
Listing KO 388870

About Pharos iBio Co., Ltd.

https://www.pharosibio.com/en/

Pharos iBio is a clinical-stage biotechnology company that specializes in drug discovery and development. The company leverages a proprietary platform based on artificial intelligence (AI) and big data to identify and create novel therapeutic candidates. Its primary focus is on developing treatments for rare and refractory diseases, with a significant emphasis on oncology. The development pipeline includes assets that are progressing through clinical trials, such as a therapy for acute myeloid leukemia.

Recent filings

Filing Released Lang Actions
감사보고서 (2022.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Pharos iBio' (주식회사 파로스아이바이오) for the fiscal year ending December 31, 2022. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes (주석). This is a comprehensive financial audit document, not an earnings release or a summary report. FY 2022
2023-04-10 Korean
연결감사보고서 (2022.12)
Annual Report Classification · 1% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Pharos iBio Co., Ltd. for the fiscal year ending December 31, 2022. It includes the independent auditor's report, consolidated financial statements (statement of financial position, comprehensive income, changes in equity, cash flows), and detailed notes. This is a formal, comprehensive annual financial report containing audited financial statements, which aligns with the definition of an Annual Report (10-K) in the provided schema. FY 2022
2023-04-10 Korean
감사보고서 (2021.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'Pharos iBio' (주식회사 파로스아이바이오). It includes the independent auditor's opinion, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an annual report (10-K) which typically includes management discussion and analysis (MD&A) and broader corporate information, nor is it a simple earnings release. Therefore, it is classified as an Audit Report (AR). FY 2021
2022-04-22 Korean
연결감사보고서 (2021.12)
Audit Report / Information Classification · 1% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for the company 'Pharos iBio' (주식회사 파로스아이바이오). It contains the independent auditor's report, consolidated financial statements (balance sheet, income statement, cash flow, etc.), and detailed notes to the financial statements for the fiscal years 2020 and 2021. This is a formal, comprehensive financial audit document, not an earnings release or a simple announcement. Therefore, it is classified as an Audit Report. FY 2021
2022-04-22 Korean
[기재정정]감사보고서 (2020.12)
Audit Report / Information Classification · 1% confidence The document is a 'Correction Report' (정정신고) for an 'Audit Report' (감사보고서) regarding financial statements. It explicitly states the reason for the correction (errors in derivative liabilities and redeemable convertible preferred stock liabilities) and provides corrected financial tables (Balance Sheet, Income Statement, etc.) and updated audit opinions. Since it is a standalone audit report document containing financial statements and audit findings, it falls under the 'Audit Report / Information' category. FY 2020
2022-04-13 Korean
[기재정정]연결감사보고서 (2020.12)
Audit Report / Information Classification · 1% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Pharus iBio, which includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, cash flow, etc.), and detailed notes. It explicitly mentions a correction (정정) of the previously filed audit report due to errors in derivative liabilities and redeemable convertible preferred stock liabilities. As it contains the full audited financial statements and the auditor's opinion, it is classified as an Audit Report (AR). FY 2020
2022-04-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.